HealthStream Announces Second Quarter 2019 Results
-
Our CEO contributed
$2.2 million of his personally ownedHealthStream stock to the Company in order to facilitate the grant of 78,520 shares of common stock to approximately 820 employees under our 2016 Omnibus Incentive Plan, which resulted in a corresponding$2.2 million charge for stock based compensation and related expense in the second quarter -
Revenues of
$63.8 million in the second quarter of 2019, up 12% from$57.0 million in the second quarter of 2018 -
Operating income of
$2.3 million in the second quarter of 2019, down 47% from$4.3 million in the second quarter of 2018, which was negatively impacted in the amount of$2.2 million by the charge associated with the stock grant to employees referenced above -
Income from continuing operations of
$2.4 million in the second quarter of 2019, down 34% from$3.7 million in the second quarter of 2018, which was negatively impacted in the amount of$1.7 million by the charge associated with the stock grant to employees referenced above -
Earnings per share (EPS) from continuing operations of
$0.07 per share (diluted) in the second quarter of 2019, which was negatively impacted by$0.05 from the charge associated with the stock grant to employees referenced above, compared to$0.11 per share (diluted) in the second quarter of 2018 -
Adjusted EBITDA1 from continuing operations of
$11.8 million in the second quarter of 2019, up 10% from$10.7 million in the second quarter of 2018
_____________________________________________________________________________
1 Adjusted EBITDA from continuing operations is a non-GAAP financial measure. A reconciliation of adjusted EBITDA from continuing operations to income from continuing operations and disclosure regarding why we believe adjusted EBITDA from continuing operations provides useful information to investors is included later in this release.
Financial Results:
Second Quarter 2019 Compared to Second Quarter 2018
Revenues for the second quarter of 2019 increased by
Revenues from our HealthStream Workforce Solutions segment were
Revenues from our HealthStream Provider Solutions segment were
Operating income was
As announced on
Income from continuing operations was
Adjusted EBITDA from continuing operations increased to
Adjusted EBITDA (from continuing and discontinued operations) was
At
Year-to-Date 2019 Compared to Year-to-Date 2018
For the first six months of 2019, revenues were
Other Business Updates
At
Financial Outlook for 2019
Below we present our updated 2019 financial guidance:
|
|
Full Year 2019 Guidance |
|||||||
Revenue |
|
|
|
|
|
|
|
|
|
Workforce Solutions |
|
$ |
207 |
|
- |
$ |
213 |
|
million |
Provider Solutions |
|
|
44 |
|
- |
|
45 |
|
million |
Consolidated |
|
$ |
251 |
|
- |
$ |
258 |
|
million |
|
|
|
|
|
|
|
|
|
|
Operating Income |
|
$ |
11.0 |
|
- |
$ |
13.0 |
|
million |
|
|
|
|
|
|
|
|
|
|
Adjusted Non-GAAP Operating Income |
|
$ |
13.2 |
|
- |
$ |
15.2 |
|
million |
|
|
|
|
|
|
|
|
|
|
Capital Expenditures |
|
|
|
|
|
$ |
36 |
|
million |
|
|
|
|
|
|
|
|
|
|
Annual Effective Income Tax Rate |
|
|
23 |
|
- |
|
25 |
|
percent |
Adjusted non-GAAP operating income guidance is a forward-looking non-GAAP financial measure, which represents GAAP operating income guidance excluding the impact of the stock grant to employees of approximately
This guidance includes the impact of the acquisition of Providigm, which is included in our Workforce Solutions segment, but does not include the impact of any other acquisitions or strategic investments that we may complete during 2019.
“We completed the first half of 2019 favorably with revenues up 15 percent and adjusted EBITDA from continuing operations up 16 percent, both over the same period last year,” said
A conference call with
Use of Non-GAAP Financial Measures
This press release presents adjusted EBITDA from continuing operations and adjusted EBITDA, both of which are non-GAAP financial measures used by management in analyzing the Company’s financial results and ongoing operational performance.
In order to better assess the Company’s financial results, management believes that net income before interest, income taxes, stock based compensation, depreciation and amortization, and changes in fair value of cost method investments (“adjusted EBITDA”) is a useful measure for evaluating the operating performance of the Company because adjusted EBITDA reflects net income adjusted for certain non-cash and non-operating items. Management also believes that adjusted EBITDA from continuing operations is a useful measure for evaluating the operating performance of the Company because such measure excludes the results of operations of the PX business that we no longer own and the gain on sale in connection with the sale of such business in
These non-GAAP financial measures should not be considered a substitute for, or superior to, measures of financial performance, which are prepared in accordance with GAAP, and may be different from non-GAAP financial measures used by other companies. Investors are encouraged to review the reconciliations of our GAAP to non-GAAP financial measures, which are set forth below in this release.
About
HEALTHSTREAM, INC.
|
||||||||||||||||
|
||||||||||||||||
|
|
Three Months Ended |
|
|
Six Months Ended |
|
||||||||||
|
|
June 30, 2019 |
|
|
June 30, 2018 |
|
|
June 30, 2019 |
|
|
June 30, 2018 |
|
||||
Revenues, net |
|
$ |
63,781 |
|
|
$ |
57,008 |
|
|
$ |
128,967 |
|
|
$ |
111,866 |
|
Operating costs and expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of revenues (excluding depreciation and amortization) |
|
|
26,806 |
|
|
|
23,236 |
|
|
|
53,667 |
|
|
|
45,484 |
|
Product development |
|
|
7,640 |
|
|
|
6,547 |
|
|
|
14,567 |
|
|
|
12,548 |
|
Sales and marketing |
|
|
9,819 |
|
|
|
8,913 |
|
|
|
19,340 |
|
|
|
17,977 |
|
Other general and administrative expenses |
|
|
10,306 |
|
|
|
8,029 |
|
|
|
20,276 |
|
|
|
15,772 |
|
Depreciation and amortization |
|
|
6,942 |
|
|
|
6,019 |
|
|
|
13,480 |
|
|
|
12,091 |
|
Total operating costs and expenses |
|
|
61,513 |
|
|
|
52,744 |
|
|
|
121,330 |
|
|
|
103,872 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income |
|
|
2,268 |
|
|
|
4,264 |
|
|
|
7,637 |
|
|
|
7,994 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other income, net |
|
|
852 |
|
|
|
476 |
|
|
|
1,674 |
|
|
|
789 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations before income tax provision |
|
|
3,120 |
|
|
|
4,740 |
|
|
|
9,311 |
|
|
|
8,783 |
|
Income tax provision |
|
|
719 |
|
|
|
1,084 |
|
|
|
2,130 |
|
|
|
1,498 |
|
Income from continuing operations |
|
|
2,401 |
|
|
|
3,656 |
|
|
|
7,181 |
|
|
|
7,285 |
|
Discontinued operations: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from discontinued operations before income tax provision |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(64 |
) |
(Loss) Gain on sale of discontinued operations |
|
|
— |
|
|
|
(1,502 |
) |
|
|
1,620 |
|
|
|
29,490 |
|
Income tax (benefit) provision |
|
|
— |
|
|
|
(391 |
) |
|
|
426 |
|
|
|
10,319 |
|
(Loss) Income from discontinued operations |
|
|
— |
|
|
|
(1,111 |
) |
|
|
1,194 |
|
|
|
19,107 |
|
Net income |
|
$ |
2,401 |
|
|
$ |
2,545 |
|
|
$ |
8,375 |
|
|
$ |
26,392 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) per share – basic: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Continuing operations |
|
$ |
0.07 |
|
|
$ |
0.11 |
|
|
$ |
0.22 |
|
|
$ |
0.23 |
|
Discontinued operations |
|
|
— |
|
|
|
(0.03 |
) |
|
|
0.04 |
|
|
|
0.59 |
|
Net income per share - basic |
|
$ |
0.07 |
|
|
$ |
0.08 |
|
|
$ |
0.26 |
|
|
$ |
0.82 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) per share - diluted: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Continuing operations |
|
$ |
0.07 |
|
|
$ |
0.11 |
|
|
$ |
0.22 |
|
|
$ |
0.23 |
|
Discontinued operations |
|
|
— |
|
|
|
(0.03 |
) |
|
|
0.04 |
|
|
|
0.59 |
|
Net income per share - diluted |
|
$ |
0.07 |
|
|
$ |
0.08 |
|
|
$ |
0.26 |
|
|
$ |
0.82 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares of common stock outstanding: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
32,394 |
|
|
|
32,312 |
|
|
|
32,366 |
|
|
|
32,205 |
|
|
|
|
32,434 |
|
|
|
32,378 |
|
|
|
32,406 |
|
|
|
32,255 |
|
Dividends declared per share |
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
1.00 |
|
HEALTHSTREAM, INC.
|
||||||||
|
||||||||
|
|
June 30, |
|
|
December 31, |
|
||
|
|
2019 |
|
|
2018 |
|
||
ASSETS |
|
|
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
120,849 |
|
|
$ |
134,321 |
|
Marketable securities |
|
|
40,737 |
|
|
|
34,497 |
|
Accounts and unbilled receivables, net |
|
|
29,836 |
|
|
|
41,004 |
|
Prepaid and other current assets |
|
|
23,059 |
|
|
|
31,612 |
|
Total current assets |
|
|
214,481 |
|
|
|
241,434 |
|
|
|
|
|
|
|
|
|
|
Capitalized software development, net |
|
|
20,764 |
|
|
|
18,352 |
|
Property and equipment, net |
|
|
28,544 |
|
|
|
15,866 |
|
Operating lease right of use assets, net |
|
|
30,774 |
|
|
|
— |
|
Goodwill and intangible assets, net |
|
|
158,093 |
|
|
|
145,522 |
|
Deferred tax assets |
|
|
251 |
|
|
|
145 |
|
Deferred commissions |
|
|
15,534 |
|
|
|
16,470 |
|
Other assets |
|
|
8,010 |
|
|
|
4,159 |
|
Total assets |
|
$ |
476,451 |
|
|
$ |
441,948 |
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND SHAREHOLDERS’ EQUITY |
|
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
|
|
Accounts payable, accrued and other liabilities |
|
$ |
31,583 |
|
|
$ |
40,793 |
|
Deferred revenue |
|
|
66,730 |
|
|
|
66,061 |
|
Total current liabilities |
|
|
98,313 |
|
|
|
106,854 |
|
Deferred tax liabilities |
|
|
13,136 |
|
|
|
11,068 |
|
Deferred revenue, non-current |
|
|
2,669 |
|
|
|
2,868 |
|
Operating lease liability, noncurrent |
|
|
32,046 |
|
|
|
— |
|
Other long-term liabilities |
|
|
616 |
|
|
|
2,211 |
|
Total liabilities |
|
|
146,780 |
|
|
|
123,001 |
|
|
|
|
|
|
|
|
|
|
Shareholders’ equity: |
|
|
|
|
|
|
|
|
Common stock |
|
|
288,900 |
|
|
|
286,597 |
|
Accumulated other comprehensive income (loss) |
|
|
23 |
|
|
|
(23 |
) |
Retained earnings |
|
|
40,748 |
|
|
|
32,373 |
|
Total shareholders’ equity |
|
|
329,671 |
|
|
|
318,947 |
|
Total liabilities and shareholders' equity |
|
$ |
476,451 |
|
|
$ |
441,948 |
|
HEALTHSTREAM, INC.
|
||||||||
|
||||||||
|
|
Six Months Ended |
|
|||||
|
|
June 30, |
|
|
June 30, |
|
||
|
|
2019 |
|
|
2018 |
|
||
Operating activities: |
|
|
|
|
|
|
|
|
Net income |
|
$ |
8,375 |
|
|
$ |
26,392 |
|
Income from discontinued operations |
|
|
(1,194 |
) |
|
|
(19,107 |
) |
Adjustments to reconcile net income to net cash provided by operating activities: |
|
|
|
|
|
|
|
|
Depreciation and amortization |
|
|
13,480 |
|
|
|
12,091 |
|
Stock based compensation |
|
|
3,074 |
|
|
|
846 |
|
Amortization of deferred commissions |
|
|
4,201 |
|
|
|
3,735 |
|
Deferred income taxes |
|
|
992 |
|
|
|
636 |
|
Provision for doubtful accounts |
|
|
48 |
|
|
|
390 |
|
Gain on equity method investments |
|
|
(69 |
) |
|
|
(5 |
) |
Other |
|
|
(84 |
) |
|
|
— |
|
Changes in assets and liabilities: |
|
|
|
|
|
|
|
|
Accounts and unbilled receivables |
|
|
12,019 |
|
|
|
3,905 |
|
Prepaid and other assets |
|
|
716 |
|
|
|
(5,570 |
) |
Accounts payable, accrued and other liabilities |
|
|
(5,280 |
) |
|
|
(10,385 |
) |
Deferred revenue |
|
|
329 |
|
|
|
3,277 |
|
Net cash provided by continuing operating activities |
|
|
36,607 |
|
|
|
16,205 |
|
Net cash used in discontinued operating activities |
|
|
— |
|
|
|
(1,003 |
) |
Net cash provided by operating activities |
|
|
36,607 |
|
|
|
15,202 |
|
|
|
|
|
|
|
|
|
|
Investing activities: |
|
|
|
|
|
|
|
|
Business combinations, net of cash acquired |
|
|
(18,018 |
) |
|
|
— |
|
Proceeds from sale of discontinued operations |
|
|
6,222 |
|
|
|
57,828 |
|
Changes in marketable securities |
|
|
(6,121 |
) |
|
|
3,397 |
|
Proceeds from sale of fixed assets |
|
|
12 |
|
|
|
|
|
Payments to acquire cost method investments |
|
|
(3,342 |
) |
|
|
— |
|
Purchases of property and equipment |
|
|
(19,598 |
) |
|
|
(3,270 |
) |
Payments associated with capitalized software development |
|
|
(8,374 |
) |
|
|
(5,094 |
) |
Net cash (used in) provided by continuing investing activities |
|
|
(49,219 |
) |
|
|
52,861 |
|
Net cash used in discontinued investing activities |
|
|
— |
|
|
|
(116 |
) |
Net cash (used in) provided by investing activities |
|
|
(49,219 |
) |
|
|
52,745 |
|
|
|
|
|
|
|
|
|
|
Financing activities: |
|
|
|
|
|
|
|
|
Proceeds from exercise of stock options |
|
|
214 |
|
|
|
2,552 |
|
Taxes paid related to net settlement of equity awards |
|
|
(985 |
) |
|
|
(300 |
) |
Payment of earn-outs related to prior acquisitions |
|
|
(37 |
) |
|
|
(37 |
) |
Payment of cash dividends |
|
|
(52 |
) |
|
|
(32,353 |
) |
Net cash used in continuing financing activities |
|
|
(860 |
) |
|
|
(30,138 |
) |
Net cash used in discontinued financing activities |
|
|
— |
|
|
|
— |
|
Net cash used in financing activities |
|
|
(860 |
) |
|
|
(30,138 |
) |
|
|
|
|
|
|
|
|
|
Net (decrease) increase in cash and cash equivalents |
|
|
(13,472 |
) |
|
|
37,809 |
|
Cash and cash equivalents at beginning of period |
|
|
134,321 |
|
|
|
84,768 |
|
Cash and cash equivalents at end of period |
|
$ |
120,849 |
|
|
$ |
122,577 |
|
Reconciliation of GAAP to Non-GAAP Financial Measures(1)
|
||||||||||||||||
|
||||||||||||||||
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
||||||||||
|
|
2019 |
|
|
2018 |
|
|
2019 |
|
|
2018 |
|
||||
GAAP income from continuing operations |
|
$ |
2,401 |
|
|
$ |
3,656 |
|
|
$ |
7,181 |
|
|
$ |
7,285 |
|
Interest income |
|
|
(884 |
) |
|
|
(510 |
) |
|
|
(1,674 |
) |
|
|
(850 |
) |
Interest expense |
|
|
30 |
|
|
|
32 |
|
|
|
51 |
|
|
|
66 |
|
Income tax provision |
|
|
719 |
|
|
|
1,084 |
|
|
|
2,130 |
|
|
|
1,498 |
|
Stock based compensation expense |
|
|
2,558 |
|
|
|
427 |
|
|
|
3,074 |
|
|
|
846 |
|
Depreciation and amortization |
|
|
6,942 |
|
|
|
6,019 |
|
|
|
13,480 |
|
|
|
12,091 |
|
Change in fair value of cost method investments |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
Adjusted EBITDA from continuing operations |
|
$ |
11,766 |
|
|
$ |
10,708 |
|
|
$ |
24,242 |
|
|
$ |
20,936 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
GAAP net income |
|
$ |
2,401 |
|
|
$ |
2,545 |
|
|
$ |
8,375 |
|
|
$ |
26,392 |
|
Interest income |
|
|
(884 |
) |
|
|
(510 |
) |
|
|
(1,674 |
) |
|
|
(850 |
) |
Interest expense |
|
|
30 |
|
|
|
32 |
|
|
|
51 |
|
|
|
66 |
|
Income tax provision |
|
|
719 |
|
|
|
693 |
|
|
|
2,556 |
|
|
|
11,817 |
|
Stock based compensation expense |
|
|
2,558 |
|
|
|
427 |
|
|
|
3,074 |
|
|
|
755 |
|
Depreciation and amortization |
|
|
6,942 |
|
|
|
6,019 |
|
|
|
13,480 |
|
|
|
12,273 |
|
Change in fair value of cost method investments |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
Adjusted EBITDA |
|
$ |
11,766 |
|
|
$ |
9,206 |
|
|
$ |
25,862 |
|
|
$ |
50,453 |
|
(1) This press release contains certain non-GAAP financial measures, including adjusted EBITDA and adjusted EBITDA from continuing operations, which are used by management in analyzing its financial results and ongoing operational performance.
This press release includes certain forward-looking statements (statements other than solely with respect to historical fact), including statements regarding expectations for the financial performance for 2019, that involve risks and uncertainties regarding
View source version on businesswire.com: https://www.businesswire.com/news/home/20190722005625/en/
Source:
Scott A. Roberts
Interim Chief Financial Officer
(615) 301-3182
ir@healthstream.com
Media:
Mollie Condra, Ph.D.
Vice President,
Investor Relations &
Communications
(615) 301-3237
mollie.condra@healthstream.com